IceCure Medical (ICCM) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company specializing in cryoablation systems using liquid nitrogen for minimally invasive tumor treatment in breast, lung, kidney, bone, and other indications.

• Lead product ProSense system and associated cryoprobes; received FDA marketing authorization for several indications and submitted for early-stage breast cancer in April 2024.

• Operations based in Israel, with global subsidiaries and exclusive Nasdaq listing since July 2023.

Financial performance and metrics

• As of September 30, 2024, held approximately $10.67 million in cash and cash equivalents, including short-term deposits.

• June 30, 2024, net tangible book value was $0.21 per Ordinary Share, with 49,517,660 shares outstanding.

• Capitalization as of June 30, 2024: $9.65 million in cash, $807,000 in short-term deposits, $10.61 million in total shareholders' equity.

Use of proceeds and capital allocation

• Net proceeds intended for business development, marketing, research and development, and general corporate purposes.

• Management retains broad discretion over allocation; proceeds may be invested in short-term, investment-grade instruments pending use.